Update on the pathogenesis, genetics and medical treatment of patterned hair loss

Journal of Drugs in Dermatology

Volumn 9, Issue 11, 2010, Pages 1412-1419

  Schweiger, Eric S ^a,b   Boychenko, Olga ^a,c   Bernstein, Robert M ^a,d  

^a Bernstein Medical Center for Hair Restoration   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYPROTERONE ACETATE; DUTASTERIDE; FINASTERIDE; MINOXIDIL; PLACEBO; TOPILUTAMIDE;

ALOPECIA; ARTICLE; DRUG EFFICACY; FEMALE TYPE ALOPECIA; GENETIC SCREENING; GENETIC VARIABILITY; HAIR FOLLICLE; HAIR GROWTH; HUMAN; LASER; MALE TYPE ALOPECIA; PATHOGENESIS; SINGLE NUCLEOTIDE POLYMORPHISM; FEMALE; GENETICS; MALE; PATHOPHYSIOLOGY; REVIEW;

ALOPECIA; FEMALE; HUMANS; MALE;

EID: 79952109801     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Hamilton JB. Patterned loss of hair in man: Types and incidence. Ann NY Acad Sci. 1951;53:708-728.
2. Norwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359-1365.
3. Ellis J, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116:452-455. (Pubitemid 32202911)
4. Muller SA. Alopecia. Syndromes of genetic significance. J Invest Dermatol. 1973;60:475-492.
5. Hamilton JB. Age, sex, and genetic factors in the regulation of hair growth in man: A comparison of Caucasian and Japanese populations. Montaaqna W, Ellis RA, editors. The Biology of Hair Growth. New York: Academic Press; 1958:399-433.
6. Setty LR. Hair patterns of the scalp of white and Negro males. Am J Phys Antropol. 1970;33:49-55.
7. Leavitt M. Understanding and management of female pattern alopecia. Facial Plast Surg. 2008;24:414-427.
8. Paik JH, Yoon JB, Sim WY, et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001;145(1):95-99.
9. Kligman A. The human hair cycle. J Invest Dermatol 1959l33:307-316.
10. Paus R, Cotsarelis G. The biology of hair follicles. New Engl J Med. 1999;341:491-497. (Pubitemid 29372890)
11. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: Pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4:1-11.
12. Jenkins EP, Andersson 5, Imperato-McGinley J, et al. Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase. J Clin Invest. 1992;89:293-300.
13. Janne OA. Androgen receptor and mechanism of androgen action. Ann Med. 1993;25:83-89. (Pubitemid 23088767)
14. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109:296-300. (Pubitemid 27394640)
15. Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol. 2006;154:609-618. (Pubitemid 43374083)
16. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247-254. (Pubitemid 8208166)
17. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144:297-304. (Pubitemid 32178809)
18. Hard S. Non-anemic iron deficiency as an etiologic factor in diffuse loss of hair of the scalp in women. Acta Derm Venereol. 1963;43:562-569.
19. Freinkel BK, Freinkel N. Hair growth and alopecia in hypothyroidism. Arch Dermatol. 1972;106:349-352.
20. Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol. 1992;36:421-427.
21. Guarrera M, Rebora A. Kenogen in female androgenetic alopecia. A longitudinal study. Derm. 2005;210:18-20. (Pubitemid 39656713)
22. Whiting DA. Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther. 1998;8:24-33. (Pubitemid 29074657)
23. Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: Clinicopathological correlations. Br J Dermatol. 2006;155;Iss 5;926-930. (Pubitemid 44564500)
24. Vierhapper H. Production rates of testosterone and of dihydrotestosterone in female pattern hair loss. Metabolism. 2003;52:927-929. (Pubitemid 36949558)
25. Futterweit W, Dunaif A, Yeh H-C, Kingsley P. The prevalance of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19:831-836. (Pubitemid 18260991)
26. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002;146(6):992-999. (Pubitemid 34779479)
27. Hillmer AM. Genetic variation in the human androgen gene is the major determinant of common early-onset androgenetic alopecia. Am J Human Genet. 2005:140-148. (Pubitemid 40848045)
28. Hicky T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metabol. 2002; 87:161-165. (Pubitemid 34084686)
29. M, Nicolas MH, Craves JC, et al. Androgens in polycystic ovarian-syndrome. Ann NY Acad Sci. 1993;687:124-135.
30. Futterweit W. Polycystic ovary syndrome: Clinical perspectives and management. Obstet Gynecol Surv. 1999;54:403-413. (Pubitemid 29247090)
31. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG Repeat Lengths) in Androgenetic Alopecia, Hirsutism, and Acne. J Cutan Med Surg. 1998;3:9-15. (Pubitemid 28352163)
32. Prodi DA. EDA2R is associated with androgenetic alopecia. J Invest Dermatol. 2008;128:2268-2270.
33. Westeberg. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metabol. 2001; 86(6):2562-8.
34. Ali I, Dawber RPR, Wojnarowska FT. The role of the androgen receptor gene CAG repeat polymorphism and X-chromosome inactivation pattern in postmenopausal female pattern hair loss: O-16. Br J Dermatol. 2008:159(Suppl 1):8-9.
35. Lyon MF. The William Allan memorial award address: X-chromosome inactivation and the location and expression of X-linked genes. Am J Hum Genet. 1988;42:8-16. (Pubitemid 18081274)
36. Levy-Nissenbaum E. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eu J Dermatol. 2005;15:339-340. (Pubitemid 41337408)
37. Hillmer AM. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Human Genet. 2008;82(3):737-43.
38. Richards BJ. Male-pattern baldness susceptibility locus at 20p11. Nature Genet. 2008;40:1282-1284.
39. Rogers NE, Avrum MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59):547-566.
40. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalp: Pharmacodynamics measured by laser Doppler velocimetry and photopulseplethysmography. J Invest Dermatol. 1984;82:515-7. (Pubitemid 14101289)
41. Galbraith GM, Thiers BH. In vitro suppression of 41. human lymphocyte activity by minoxidil. Int J Dermatol. 1985;24:249-251. (Pubitemid 15096545)
42. Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexylnicotinate in alopecia. Br J Dermatol. 1987;117:668-669. (Pubitemid 18078457)
43. Murad S, Pinnell SR. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem. 1987;262:11973-11978. (Pubitemid 17131662)
44. Nuck BA, Fogelson SL, Lucky AW. Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Arch Dermatol. 1987;123:59-61. (Pubitemid 17135822)
45. Pinnell SR, Murad S. Effects of minoxidil on cultured human skin fibroblasts. Dermatologica. 1987;175(Suppl 2):12-18. (Pubitemid 17166164)
46. Kvedar JC, Baden HP, Levine L. Selective inhibition byminoxidil of prostacycline production by cells in culture. Biochem Pharmacol. 1988;37:867-874. (Pubitemid 18058458)
47. O'Barr TP, Swanson EW, Fitzpatrick JE, Corby DG. Effect of minoxidil on platelet function and the synthesis of prostaglandins in platelets. J Lab Clin Med. 1989;114:575-578. (Pubitemid 19285578)
48. Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17:276-281. (Pubitemid 20321655)
49. Buhl AE, Waldon DJ, Conrad SJ, et al. Potassium channel conductance: A mechanism affecting hair growth in vitro and in vivo. J Invest Dermatol. 1992;98:315-319.
50. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138:407-411. (Pubitemid 28145505)
51. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in man. J Am Acad Dermatol. 2002;47:377-385.
52. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled double-blind clinical trial of a novel formulation of 5% topical minoxidil topical foam vs. placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57:767-774. (Pubitemid 47553065)
53. Lucky AW, Picquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541-553. (Pubitemid 38393163)
54. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three- and 4-year results. J Am Acad Dermatol. 2006;55:71-74. (Pubitemid 43884854)
55. Kaufman KD. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male. J Am Acad Dermatol. 1998;39:578-89. (Pubitemid 28465881)
56. Price VH, Menefee E, Sanchez M, et al. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46:517-523.
57. Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: Four cases responding to finasteride. J Am Acad Dermatol. 2002;47:733-739. (Pubitemid 35239335)
58. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs.finasteride. J Am Acad Dermatol. 2006;55:1014-1023. (Pubitemid 44716474)
59. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4:637-640.
60. Kucerova R, Bienova M, Novotny R, et al. Current therapies of female androgenetic alopecia and use of fluridil, a novel topical antiandrogen. Scripta Medica (Brno). 2006;79:35-48. (Pubitemid 46508611)
61. Neumann F. The antiandrogen cyproterone acetate: Discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102;1-32.